UMB Bank’s Enanta Pharmaceuticals ENTA Stock Holding History

UMB Bank’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-978	Closed	-$5.4K	–	2140
2025 Q1	$5.4K	Buy	+978	New	+$6.04K	﹤0.01%	1737

Other funds holding ENTA

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UMB Bank's ENTA Position: Q2 2025 in Review

UMB Bank sold out of Enanta Pharmaceuticals (ENTA) in Q2 2025, closing a stake of 978 shares — an estimated $5.4K sold.

UMB Bank first reported a position in ENTA in Q1 2025 and held it in 1 quarter. The position peaked at $5.4K in Q1 2025. 107 funds tracked by Wall St. Rank hold ENTA as of Q2 2025.

UMB Bank reported no remaining Enanta Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
UMB Bank sold 978 Enanta Pharmaceuticals shares in Q2 2025, an estimated $5.4K.
UMB Bank first reported a position in Enanta Pharmaceuticals in Q1 2025 and held it in 1 quarter.
UMB Bank's Enanta Pharmaceuticals position peaked at $5.4K in Q1 2025.
107 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2025.

Based on UMB Bank's 13F filing for Q2 2025, filed 10 Jul 2025.